![]() Under the agreement, Voyager provided Sangamo with access to a TRACER capsid to be combined with Sangamo’s zinc finger transcriptional regulators (ZF-TRs) designed to treat prion disease. announced a definitive license agreement for a potential treatment of prion disease. Licensing agreement with Sangamo: In June, Voyager and Sangamo Therapeutics, Inc.This initiative further expands Voyager’s portfolio of Alzheimer’s programs including its anti-tau antibody program and siRNA tau knockdown gene therapy research initiative. Preliminary data in mice have shown vectorized antibody target engagement. The new initiative leverages Voyager’s vectorized antibody expertise to express an anti-Aβ antibody to target amyloid plaques. Launch of new vectorized anti-Aβ antibody early research initiative for Alzheimer’s disease: Voyager today announced an early research initiative investigating a gene therapy comprising a vectorized anti-Aβ antibody delivered via a TRACER capsid for the potential one-time treatment of Alzheimer’s disease.Key Milestones Achieved in Q2 2023 and Subsequent Period: ![]() ![]() Our anti-tau antibody VY-TAU01 remains on track for IND in the first half of 2024, and we continue to advance our growing pipeline of wholly-owned and partnered CNS gene therapies leveraging our neurotropic TRACER capsids.” “We are encouraged by recent approvals in Alzheimer’s disease, and we believe this establishes a path forward for new approaches to existing targets, as well as new targets, to help address the heterogeneity of the massive Alzheimer’s disease population. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “The introduction today of Voyager’s vectorized anti-Aβ gene therapy research initiative expands our Alzheimer's disease portfolio, complementing our anti-tau antibody and tau knock-down gene therapy programs,” said Alfred W. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported second quarter 2023 financial and operating results. 03, 2023 (GLOBE NEWSWIRE) - Voyager Therapeutics, Inc. Presented validating preclinical results including increased brain transduction of IV-administered TRACER™ capsids across multiple non-human primate species at ASGCT 2023. Executed license agreement with Sangamo for prion disease treatment. Introduced new vectorized anti-Aβ antibody gene therapy research initiative, expanding Alzheimer’s disease portfolio.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |